Hypoxaemia in children: “abnormal” values may be misleading

Duke et al are to be commended for their interesting report aimed to determine normal oxygen saturation values in healthy infants and children and to assess the performance of oxygen saturation values in healthy infants. The editors will decide, as before, whether to publish it in a future paper issue.

If you have a burning desire to respond to a paper published in ADC or FE&M, why not make use of our “rapid response” option? Log on to our website (www.archdischild.com), find the paper that interests you, click on “full text” and send your response by email by clicking on “submit a response”. Providing it isn’t libellous or obscene, it will be posted within seven days. You can retrieve it by clicking on “read eLetters” on our homepage.

LETTERS

Hypoxaemia in children: “abnormal” values may be misleading

Duke et al. aim to determine normal oxygen saturation values in healthy infants and children and to assess the performance of oxygen saturation values in healthy infants. This latter finding has obvious practical implications, as high altitude native children, with higher baseline oxygen saturation levels than newcomers or resident non-native evidence that can be applicable to this setting is a major public health challenge for all of us working in those parts of the world.

L Huicho
Department of Paediatrics, Universidad Nacional Mayor de San Marcos and Instituto de Salud del Niño, Lima, Peru; lhhuicho@viabcp.com

References

Response to Duke et al.

We read with interest the article by Duke et al. regarding hypoxaemia in acute respiratory and non-respiratory illnesses in infants and children in developing countries published recently in Archives. The authors have rightly pointed out the limited availability of published data on the incidence, significance or clinical signs predicting hypoxaemia in infants less than three months of age. With similar concerns we had conducted a study in infants less than two months, a part of which was published in the Archives. We found that tachypnoea, defined as RR>60/min, predicted hypoxia with 80% sensitivity and 68% specificity. In that study we defined six functional and behavioural responses as predictors of hypoxia (table 1). Five of these six variables had a very good sensitivity to detect hypoxia. A very high prevalence of hypoxaemia in the population studied by Duke et al. is rather intriguing. Out of total 257 sick neonates and children 52%, were hypoxic. Among children with acute lower respiratory infection (ALRI) 73% and those with non-ALRI 32% were hypoxic. In an ongoing study we have measured oxygen saturation (by Nellcor® oximeter) in a prospective cohort of 683 children 2–59 months brought to paediatric emergency department (ED) with any respiratory symptom. Oxygen saturation using a fingertip sensor in these children at the time of arrival to ED ranged from 78–99%. The overall prevalence of hypoxia defined as SpO₂ <90% was 4.5% (table 2). An additional 5.1% children had borderline hypoxaemia, i.e. a SpO₂ value of 90%. This is similar to a prevalence of 5.9% hypoxia defined as SpO₂ <90% in Gambian children, 2–33 months of age, reported by Usen et al. Even in our previous study of 200 infants less than two months, only 38.5% of the sick infants attending ED were hypoxic. A systematic review of studies on prevalence and predictors of hypoxiaemia in children by Lozano et al. found that the prevalence of hypoxiaemia was dependent upon a number of factors including the setting of the study. The prevalence ranged from 6–9% in outdoor setting to 31–43% in emergency departments to a maximum of 47% in hospitalised children.

Yet, in our study, which represents the situation near sea level (Chandigarh topographically) and the setting of an emergency department, the prevalence of hypoxaemia is much lower than that reported at heights. In light of our data and published literature, we believe that either the definition of hypoxia used by Duke et al. is too liberal or the children with respiratory symptoms living at high altitude decompensate more frequently to develop hypoxia. More information is needed in this respect to formulate
guidelines for general use. The cumulative data clearly suggest that hypoxaemia is more frequent in children living at high altitude. Interestingly most studies including that of Duke et al on this subject in children 2 to 59 months have been from high altitudes. It is more likely that geographic location, 1600m above sea level is responsible for the high frequency of “hypoxaemia” in their patient population. This, however, may not necessarily reflect the need for oxygen therapy. If definition of hypoxaemia suggested by Duke et al were to be applied as a guideline to oxygen therapy makes any difference to outcome of patients labeled as hypoxicemic using cut off limits proposed by Duke et al. It may also be worthwhile to conduct studies with a large sample size at sea level (plains) and in various settings before reaching a conclusion about SpO2 cut off for hypoxia at heights.

S Singhi, B Bharti
Department of Pediatrics, Advanced Pediatrics Centre, Postgraduate Institute of Medical Education & Research, Chandigarh-160 012, India

References
2 Rajesh VT, Singh S, Katoria S. Tachypnoea is a good predictor of hypoxia in acutely ill children. Arch Dis Child 2000;82:46–49.

Hypoxaemia in developing countries

Drs Huicho, Singi, and Bharti make the important points that definitions of hypoxaemia should be based on altitude-specific normal values and that further research at sea level and higher altitudes is needed. An altitude-specific definition of hypoxaemia (being an arbitrary value of SpO2 more than 2 or 3 standard deviations below the normal population mean) may be different from the threshold SpO2 for giving oxygen. These considerations for giving oxygen are at what level of SpO2 (at different altitudes) oxygen is beneficial, local resource availability, and, in an individual child, confounding factors including the duration of exposure to altitude, age, or co-existent disease such as brain injury, severe anaemia, pulmonary hypertension, and cardiac failure.

We studied Papua New Guinean neonates and children living at an altitude of 1600m to determine normal range of oxygen saturation. Hypoxaemia in our study was a SpO2 more than 2SD below the mean. In practice our threshold for giving oxygen to sick children (SpO2<85%; more than 3SD below the mean) was lower than this because of limited oxygen availability. However there is evidence that this is safe and effective. We stated that without further evaluation this should not be applied to hospitals at substantially lower altitudes than 1600m or in areas where oxygen availability is greater.

In comparing the prevalence of hypoxaemia between studies in different health facilities referral and selection biases are likely. Hypoxaemia will be more common in emergency departments of referral hospitals than at primary care settings, and more common still among children requiring hospital admission. The prevalence of hypoxaemia in hospitals depends on thresholds for admission and case-mix. The 491 children in our study constituted about 20% of all the children admitted during the course of the study. A specialist paediatrician, whose practice was to oversee the care of sicker children, enrolled many of the patients, so this was a further source of selection bias. The much lower overall prevalence of hypoxaemia observed by Drs Singhi and Bharti in their emergency department population is therefore understandable. Of note the prevalence of hypoxaemia among sick neonates admitted to Goroka Hospital (43%) was similar to the prevalence among young infants (<2 months of age) attending the emergency department in Chandigarh (38.5%).

It is interesting to consider the effects of altitude on hypoxaemia in children with pneumonia. Some populations living at higher altitudes have a greater tendency to pulmonary hypertension; this susceptibility may be genetically determined and supports Dr Huicho’s statement that ethnic differences in SpO2, at the same altitude are important. At altitude in response to hypoxia, pulmonary blood flow is shunted to the lung apices associated with redistribution of vasoactivity in the basal lung. This may have an adverse effect on ventilation perfusion matching in the supine position. In addition cardiac expression of natriuretic peptides increases in parallel with pulmonary artery pressure. These and other pathophysiological changes may account for the greater severity and prolonged duration of hypoxaemia seen at higher altitudes. It is important to evaluate the simple intervention of nursing children with pneumonia and hypoxaemia at high altitude in an inclined head-up position, rather than supine, to determine if this reduces the severity of hypoxaemia. There is a need for more evidence about the prevalence of hypoxaemia at sea level and different altitudes; which children benefit from oxygen; for how long oxygen should be given and the best ways to deliver oxygen in remote settings. Controlled trials of oxygen in mild hypoxaemia may not be justified for ethical reasons, but other evidence will be informative. Before the introduction of pulse oximetry we set a threshold SpO2 85%. The severe pneumonia case-fatality rate fell from 10% (26/258) pre-pulse oximetry to 5.8% (65/1116) 2 years later.1

In highland PNG children cyanosis was only detected in 44% of those with an SpO2<90%. Although there will be confounders in the before-and-after analysis of outcome, we conclude that clinical signs must miss a significant proportion of children who would otherwise benefit from supplementary oxygen. The introduction of a protocol for the administration of oxygen based on a threshold SpO2 of 85% (more than 3 SD below the mean for normal children in Goroka) resulted in improved outcomes, and was within available resources.

The costs of oxygen and logistics of transporting cylinders are major problems in many developing countries; Dr Huicho is right that these are important public health challenges. They call for innovative research and development into how best to supply oxygen to children who need it. The role of oxygen concentrators need to be further explored; the combination of concentrators with pulse oximetry would be appropriate technology for many hospitals in developing countries. In countries where the availability of oxygen is crucial to the management of more than 20% of children hospitalised worldwide should be a very high priority; oxygen is one such drug.

T Duke
Centre for International Child Health, University Department of Paediatrics, Royal Children’s Hospital, Parkville 3052, Victoria, Australia.
trevor.duke@rch.org.au

References
5 Rajesh VT, Singi S, Katoria S. Tachypnoea is a good predictor of hypoxia in acutely ill children. Arch Dis Child 2000;82:46–49.
already contributed so much to their own survival it is inappropriate to perceive refugees simply as victims who require help. Conventional Western responses may be thus inappropriate and ineffective; we need to provide a range of services that are both flexible and innovative. Our work with Bosnian refugee families is an excellent example of therapeutic innovation.1 It has referred to “therapeutic presence” and “therapeutic witnessing” as opposed to formal psychotherapy. All of these children have a story to tell although for some the story will be more coherent than for others. In Western psychological terms their plight is somewhat comparable with that of abused children in the care system. Making sense of their experiences in a coherent way is a significant developmental task for them. It is also potentially a shared experience as it is something these children will have in common with others in their family, peers, and wider refugee community. Life story work is an area in which many child mental health professionals, working with abused children, already have considerable expertise. If we were to like to draw attention to the importance of a developmental approach when working with refugee children, it is a mistake to assume that their development parallels that of children growing up in their own country. Developmental pathways, as well as having occurred in a different cultural context, may have been significantly, and sometimes adversely, influenced by war and refugee experiences.

Pharmacogenomic can give children safer medicines

I read with great interest Clarkson and Chooonara’s paper on the fatal suspected adverse drug reactions (ADRs) in the UK, and I strongly agree with their conclusions, namely that an evidence based approach to drug treatment is needed to minimise fatalities due to drug toxicity in children.1 However, recent evidence also suggests that we are now ready for a gene based approach to drug treatment allowing to further minimise the occurrence and the severity of adverse drug reactions.2 Increasingly complex genetic knowledge can already be used to elucidate mechanisms underlying the adverse events of drugs, particularly for pharmaceuticals with biological events, and potentially even to predict adverse events before human exposure.3

In a recently published systematic review, the authors found that more than half of the drugs cited in ADR studies are metabolised by at least one enzyme with a variant allele known to cause poor metabolism, suggesting that genetic variability in drug metabolising enzymes is likely to be an important contributor to the incidence and severity of ADRs.4 In Clarkson and Choonara’s paper it is reported that anticonvulsants, which is the group of drugs most frequently associated with fatal ADRs. Anticonvulsants are indeed among the drugs mostly concerned by enzymes with variant alleles associated with poor metabolism.5 A number of polymorphisms in the cytochrome 450 enzymes (CYPs), important in the metabolism of anticonvulsants have been reported. For example, the enzyme CYP1A2, which is one important metabolic pathway for carbamazepine and phenitoitin, has only one identified variant allele with poor metabolism, but there is a significant prevalence of poor metabolisers for CYP1A2 among the general population. Other common polymorphisms concern the enzyme CYP2C19, resulting in altered metabolism of both phenobarbital and phenitoitin.6

Substantial investments are being made within the pharmaceutical and biotechnology industries to use genomic strategies for the development of therapeutic agents targeted for specific subgroups of the population. Such pharmacogenomic studies also permit a more rational and safer use of existing therapies. It is my hope that this translation of functional genomics into rational therapeutics will not neglect the right of children to receive safer and more efficient pharmacotherapy, and that the pace of this transformation will not be limited by the lack of adequate pharmacogenomic information to practising paediatricians.

E Webb, M Davies
Department of Child Health, University of Wales College of Medicine, UK Correspondence to Dr Webb webbev@cf.ac.uk

References

Ketocid acid levels may alter osmoticity in diabetic ketoacidosis and precipitate cerebral edema

I strongly agree with their conclusions, I read with great interest Clarkson and Chooonara’s paper on the fatal suspected adverse drug reactions (ADRs) in the UK, and I strongly agree with their conclusions, namely that an evidence based approach to drug treatment is needed to minimise fatalities due to drug toxicity in children.1 However, recent evidence also suggests that we are now ready for a gene based approach to drug treatment allowing to further minimise the occurrence and the severity of adverse drug reactions.2 Increasingly complex genetic knowledge can already be used to elucidate mechanisms underlying the adverse events of drugs, particularly for pharmaceuticals with biological events, and potentially even to predict adverse events before human exposure.3

In a recently published systematic review, the authors found that more than half of the drugs cited in ADR studies are metabolised by at least one enzyme with a variant allele known to cause poor metabolism, suggesting that genetic variability in drug metabolising enzymes is likely to be an important contributor to the incidence and severity of ADRs.4 In...

Downloaded from http://adc.bmj.com/ on July 7, 2017 - Published by group.bmj.com

PostScript

www.archdischild.com

In a study of DKA we found that the mean osmolality at admission was 318 (SD 12.9; range 291–337). Further, we also found that the calculated osmolality (calculated osmolality = 1.86( Na + + K + ) + Urea + Glucose) was only 289 (range 282–304). This suggests hypertonicity is common in DKA and the calculated osmolality underestimates the true osmolality. The mean osmolal gap was 29 (range 14–48). The osmolal gap between true and the calculated osmolality, is made up of unmeasured substances like ketoads. The osmolality of ketoads have been ignored in the past, as they are considered to be biologically inactive and not contributing to osmotonicity.1 A study done by us (submitted for publication) has demonstrated that ketoads (acetoadsates) are osmotically active. (Acetoadsate can influence fluid shifts across a semipermeable membranes. This is in contrast to urea, which is not osmotically active.) Osmolality, osmolal gap, and ketone bodies are not measured routinely during the management of DKA. A rapid fall in ketone body levels can result in a fall in body osmolality and osmotonicity of the serum and lead to cerebral edema. In a recent paper looking at the risk factors for development of cerebral edema in DKA the author noted that since none of the “relevant variables” (serum glucose concentration, rate of hydration, rate of glucose concentration during therapy, rate of fluid and sodium administration) were associated with the risk of cerebral edema, their data did not support the theory that a rapid decrease in extra cellular osmolality did not occur. In summary we suggest that changes in ketone body levels be considered, as a factor that can be partially responsible for the cerebral edema often seen during treatment of DKA. We will be glad to share our data at any summit of experts convened to study the enigma of cerebral edema in DKA.

J M Puliyel, V Bhambhani
St Stephens Hospital, Tis Hazari, Delhi, India

Correspondence to Dr Puliyel, puliyel@vxl.com

References
BOOK REVIEWS

The Lazarus case, Life and Death Issues in Neonatal Intensive Care


When things go badly wrong in the perinatal period there has developed a culture in many "advanced societies" that demands a search for someone to blame. This search for guilt, accountability, punishment, and recompense often results in litigation.

In this thought provoking book John D Lantos describes such lawsuits as "our public morality plays" and uses his experience as a neonatologist, expert witness, and ethicist to create, debate, and crystallise relevant issues of ethics related to the neonatal intensive care of a fictional preterm infant who should have died but did not—The Lazarus Case.

A fictitious neonatologist, Dr Miller, decides to stop resuscitation of a very preterm infant who seems past reasonable care. The baby who might have died survived with severe neurological problems and the parents sue Dr Miller, alleging that stopping treatment was negligent. John Lantos places himself in the role of expert witness and uses questions put by the plaintiff's lawyers to explore the moral, ethical, legal, and social factors and to illustrate the ambiguities, misunderstandings, responsibilities, and evasions highlighted by the perinatal care of a 25 week gestation infant.

A key question put to Dr Lantos by one lawyer was "Can studying philosophy tell you whether what a doctor does in a particular case is right or wrong?" Probably not is the final conclusion reached by Dr Lantos, but it was just as unlikely that definitive guidance would come from sociology, religious doctrine, strict medical protocols, or any other single source.

There have been many attempts over the past half century to face and explain the moral dilemmas associated with our attempts to save the lives, prevent damage, and encourage optimal development of critically ill preterm infants. The Lazarus Case reviews in a most effective, compelling, erudite, and compassionate way the enormous complexity of these issues. It is highly recommended to all who are concerned with the care of preterm infants and their families and is essential reading for those required to provide medico-legal advice on life and death issues in neonatal intensive care.

Forrester Cockburn

Problems in Paediatric Drug Therapy, 4th edn


There is increasing interest in both the clinical and scientific aspects of drug therapy in paediatric patients. This text book by the American Pharmaceutical Association is aimed at the North American market.

It is a reference book aimed at paediatric pharmacists. It covers a wide range of the problems associated with paediatric drug therapy, with chapters on the administration of drugs, fetal toxicity, drugs in breast milk, and both poisoning and drug toxicity, and also specific clinical areas, for example chemotherapy. There did not appear to be any order in the chapters. It would seem more appropriate to put chapter 13 on neonatal doses after chapter 3 on drugs in breast milk than after a chapter on chemotherapy.

There are several chapters with information on the dosage of medicines and it is of interest that these are divided into three separate chapters, one for neonates, one for infants/children and adolescents and one specifically for intravenous drugs. Despite having a chapter specifically on intravenous drugs, the chapters on drug dosing on both neonates and infants/children and adolescents contains details on the doses required for intravenous administration. This makes the book far more difficult to use. The dosage guidance is far less user friendly than publications such as Medicines for Children or the Neonatal Formulary.

It is for this reason I would not therefore recommend Paediatric Pharmacy departments to buy a copy of the book.

I Choonara